1-Deoxymannojirimycin is a specific inhibitor of class I α-1,2-mannosidase (IC50 = 0.02 μM), a key enzyme for N-glycan processing in the endoplasmic reticulum and Golgi and for targeting misfolded proteins for translocation out of the endoplasmic reticulum and degradation by the proteasome. By inhibiting α-1,2-mannosidase activity, this compound generates N-linked oligosaccharides with high mannose content, preventing misfolded protein degradation. This compound has been used for studies on glycoprotein processing and as a model for the development of anticancer and antiviral therapies.
Deoxymannojirimycin has been shown to be a potent inhibitor of the mammalian Golgi alpha- mannosidase 1 activity, blocking the conversion of high-mannose oligosaccharides to complex-type oligosaccharides. However, it does not inhibit the biosynthesis of lipid- linked oligosaccharides.
Selective inhibitor of a-mannosidase
1) Bischoff et al. (1986), The use of 1-deoxymannojirimycin to evaluated the role of various alpha-mannosidases in oligosaccharide processing in intact cells; J. Biol. Chem., 261 4766
2) Bischoff et al. (1984), The effect of 1-deoxymannojirimycin on rat liver alpha mannosidases.; Biochem. Biophys. Res. Commun., 125 324
3) Fuhrmann et al. (1984), Novel mannosidase inhibitor blocking conversation of high mannose to complex oligosaccharides; Nature, 307 755
4) Miyake and Nagai (2009), Inhibition of alpha-mannosidase attenuates endoplasmic reticulum stress-induced neuronal cell death; Neurotoxicology, 30 144
5) Tai et al. (2011), Production of lentiviral vectors with enhanced efficiency to target dendritic cells by attenuating mannosidase activity of mammalian? cells; J. Biol. Eng., 5? 1
6) Lee et al. (2012), Construction of stable producer cells to make high-titer lentiviral vectors for dendritic cell-based vaccination; Biotechnol. Bioeng., 109 1551
